Cargando…
Concurrent inflammatory bowel disease and primary sclerosing cholangitis: a review of pre- and post-transplant outcomes and treatment options
Primary Sclerosing Cholangitis (PSC) is a chronic cholestatic liver disease which is associated with Inflammatory Bowel Disease (IBD) in 70% of cases. It seems PSC/IBD is a distinct phenotype that is different from PSC, and IBD alone. Hence, we review the epidemiology, pathogenesis, natural course a...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Shaheed Beheshti University of Medical Sciences
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520392/ https://www.ncbi.nlm.nih.gov/pubmed/37767322 http://dx.doi.org/10.22037/ghfbb.v16i2.2589 |
_version_ | 1785109908565262336 |
---|---|
author | Hatami, Behzad Pasharavesh, Leila Sharifian, Afsaneh Zali, Mohammad Reza |
author_facet | Hatami, Behzad Pasharavesh, Leila Sharifian, Afsaneh Zali, Mohammad Reza |
author_sort | Hatami, Behzad |
collection | PubMed |
description | Primary Sclerosing Cholangitis (PSC) is a chronic cholestatic liver disease which is associated with Inflammatory Bowel Disease (IBD) in 70% of cases. It seems PSC/IBD is a distinct phenotype that is different from PSC, and IBD alone. Hence, we review the epidemiology, pathogenesis, natural course and management of PSC/IBD before and after LT for PSC. Extensive colitis, rectal sparing, backwash ileitis, and mild symptoms are the characteristics of IBD coexisting with PSC. Moreover, PSC patients with concurrent IBD have higher risk of cholangiocarcinoma, and colorectal neoplasia predominantly in right colon and at younger age. Therefore, it is essential to monitor these individuals continuously. It is interesting to note that the course of IBD (ulcerative colitis) after liver transplantation (LT) for PSC varies greatly, and some patients may develop worsening colitis after LT despite immunosuppressive regimens. As well, management of these patients was discussed in this review. |
format | Online Article Text |
id | pubmed-10520392 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Shaheed Beheshti University of Medical Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-105203922023-09-27 Concurrent inflammatory bowel disease and primary sclerosing cholangitis: a review of pre- and post-transplant outcomes and treatment options Hatami, Behzad Pasharavesh, Leila Sharifian, Afsaneh Zali, Mohammad Reza Gastroenterol Hepatol Bed Bench Review Article Primary Sclerosing Cholangitis (PSC) is a chronic cholestatic liver disease which is associated with Inflammatory Bowel Disease (IBD) in 70% of cases. It seems PSC/IBD is a distinct phenotype that is different from PSC, and IBD alone. Hence, we review the epidemiology, pathogenesis, natural course and management of PSC/IBD before and after LT for PSC. Extensive colitis, rectal sparing, backwash ileitis, and mild symptoms are the characteristics of IBD coexisting with PSC. Moreover, PSC patients with concurrent IBD have higher risk of cholangiocarcinoma, and colorectal neoplasia predominantly in right colon and at younger age. Therefore, it is essential to monitor these individuals continuously. It is interesting to note that the course of IBD (ulcerative colitis) after liver transplantation (LT) for PSC varies greatly, and some patients may develop worsening colitis after LT despite immunosuppressive regimens. As well, management of these patients was discussed in this review. Shaheed Beheshti University of Medical Sciences 2023 /pmc/articles/PMC10520392/ /pubmed/37767322 http://dx.doi.org/10.22037/ghfbb.v16i2.2589 Text en © 2023, Gastroenterology and Hepatology From Bed to Bench (GHFBB) https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/) which permits others to copy and redistribute the material just in noncommercial usages, provided the original work is properly cited. |
spellingShingle | Review Article Hatami, Behzad Pasharavesh, Leila Sharifian, Afsaneh Zali, Mohammad Reza Concurrent inflammatory bowel disease and primary sclerosing cholangitis: a review of pre- and post-transplant outcomes and treatment options |
title | Concurrent inflammatory bowel disease and primary sclerosing cholangitis: a review of pre- and post-transplant outcomes and treatment options |
title_full | Concurrent inflammatory bowel disease and primary sclerosing cholangitis: a review of pre- and post-transplant outcomes and treatment options |
title_fullStr | Concurrent inflammatory bowel disease and primary sclerosing cholangitis: a review of pre- and post-transplant outcomes and treatment options |
title_full_unstemmed | Concurrent inflammatory bowel disease and primary sclerosing cholangitis: a review of pre- and post-transplant outcomes and treatment options |
title_short | Concurrent inflammatory bowel disease and primary sclerosing cholangitis: a review of pre- and post-transplant outcomes and treatment options |
title_sort | concurrent inflammatory bowel disease and primary sclerosing cholangitis: a review of pre- and post-transplant outcomes and treatment options |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520392/ https://www.ncbi.nlm.nih.gov/pubmed/37767322 http://dx.doi.org/10.22037/ghfbb.v16i2.2589 |
work_keys_str_mv | AT hatamibehzad concurrentinflammatoryboweldiseaseandprimarysclerosingcholangitisareviewofpreandposttransplantoutcomesandtreatmentoptions AT pasharaveshleila concurrentinflammatoryboweldiseaseandprimarysclerosingcholangitisareviewofpreandposttransplantoutcomesandtreatmentoptions AT sharifianafsaneh concurrentinflammatoryboweldiseaseandprimarysclerosingcholangitisareviewofpreandposttransplantoutcomesandtreatmentoptions AT zalimohammadreza concurrentinflammatoryboweldiseaseandprimarysclerosingcholangitisareviewofpreandposttransplantoutcomesandtreatmentoptions |